Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to track every genome-editing breakthrough Caribou Biosciences reports while deciphering 200-page SEC documents? Early-stage biotech filings are dense with trial data, CRISPR patent updates, and cash-runway details that move the stock overnight.
Stock Titan turns those complexities into clarity. Our AI reads each Caribou Biosciences annual report 10-K simplified, flags R&D spend trends, and highlights chRDNA milestones so you can focus on what drives valuation. Need the latest Caribou Biosciences quarterly earnings report 10-Q filing? You’ll get real-time alerts plus an AI summary that connects lab progress to financial burn.
Looking for insider sentiment? Instantly scan Caribou Biosciences Form 4 insider transactions real-time to see when executives buy after positive CB-010 data. Our coverage also answers common searches such as “Caribou Biosciences insider trading Form 4 transactions”, “Caribou Biosciences proxy statement executive compensation”, and “Caribou Biosciences 8-K material events explained.”
- AI-powered summaries strip the jargon from clinical-trial risk factors—perfect for understanding Caribou Biosciences SEC filings explained simply.
- Real-time EDGAR feeds ensure you never miss an 8-K announcing dose-expansion data.
- Expert context connects share-based compensation shifts to dilution risk in one click.
Whether you’re modeling cash needs, comparing CAR-T pipelines, or understanding Caribou Biosciences SEC documents with AI, Stock Titan delivers the Caribou Biosciences earnings report filing analysis you need—without the endless page-scrolling.
Caribou Biosciences reported a quarterly net loss of $54.1 million and a six-month net loss of $94.1 million, with licensing and collaboration revenue of $2.7 million for the quarter and $5.0 million for the six months ended June 30, 2025. Management reported cash, cash equivalents and marketable securities of $183.9 million as of June 30, 2025, which it expects will fund operations for at least the next 12 months.
The company announced a strategic pipeline prioritization that discontinues preclinical research and two programs (GALLOP and AMpLify) and reduced the workforce by 47 employees (~32%). It recorded $12.15 million of impairment charges and a $9.16 million impairment of its equity investment in Edge, remeasured the MSKCC success payments liability to zero following termination notice, and ended the quarter with total assets of $220.9 million and an accumulated deficit of $542.5 million.
Caribou Biosciences, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update. The press release is attached as Exhibit 99.1 to this Current Report and is incorporated by reference into the disclosure.
The filing specifies that the Item 2.02 information (including Exhibit 99.1) is being furnished and therefore is not deemed "filed" under the Exchange Act, meaning it is provided for investor information without extending Section 18 liabilities. The 8-K itself does not include separate financial tables or statements beyond the furnished press release.
FAQ
What is the current stock price of Caribou Biosciences (CRBU)?
What is the market cap of Caribou Biosciences (CRBU)?
